Skip to content

Study · Randomized controlled trial · n = 24 · 2008

6 results

Effect of teriparatide on early bone loss after kidney transplantation.

Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, Haas M

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons1 Sept 2008Cited by 67 (Europe PMC)

PMID18786230 (opens in a new tab)DOI10.1111/j.1600-6143.2008.02327.x (opens in a new tab)PepBankPUB-18786230
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In kidney transplant recipients, femoral neck BMD remained stable with teriparatide, while placebo recipients had significant decreases.

    In plain wordsIn kidney transplant recipients, hip bone density remained stable with teriparatide, while it decreased significantly with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFemoral neck BMD
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Femoral neck BMD was stable in the teriparatide group, but decreased significantly in the placebo group.
    1 context sentence
    Summary · context
    In a 6-month double-blind, randomized trial, 26 kidney transplant recipients were treated with daily subcutaneous injections of 20 microg teriparatide (PTH 1-34) or placebo.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In kidney transplant recipients, lumbar spine BMD remained unchanged in both teriparatide and placebo groups.

    In plain wordsIn kidney transplant recipients, spine bone density remained unchanged in both teriparatide and placebo groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine BMD
    Study

    n = 24

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Lumbar spine and radial BMD, histomorphometric bone volume and bone matrix mineralization status remained unchanged in both groups.
    2 context sentences
    Summary · context
    In a 6-month double-blind, randomized trial, 26 kidney transplant recipients were treated with daily subcutaneous injections of 20 microg teriparatide (PTH 1-34) or placebo.
    Summary · context
    A total of 24 out of 26 patients completed the study.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In kidney transplant recipients, radial BMD remained unchanged in both teriparatide and placebo groups.

    In plain wordsIn kidney transplant recipients, forearm bone density remained unchanged in both teriparatide and placebo groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRadial BMD
    Study

    n = 24

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Lumbar spine and radial BMD, histomorphometric bone volume and bone matrix mineralization status remained unchanged in both groups.
    2 context sentences
    Summary · context
    In a 6-month double-blind, randomized trial, 26 kidney transplant recipients were treated with daily subcutaneous injections of 20 microg teriparatide (PTH 1-34) or placebo.
    Summary · context
    A total of 24 out of 26 patients completed the study.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In kidney transplant recipients, serologic bone markers decreased similarly in both teriparatide and placebo groups.

    In plain wordsIn kidney transplant recipients, blood bone markers decreased similarly with teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerologic bone markers
    Study

    n = 24

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Serologic bone markers were similarly reduced in both groups throughout the study.
    2 context sentences
    Summary · context
    In a 6-month double-blind, randomized trial, 26 kidney transplant recipients were treated with daily subcutaneous injections of 20 microg teriparatide (PTH 1-34) or placebo.
    Summary · context
    A total of 24 out of 26 patients completed the study.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In kidney transplant recipients, histomorphometric bone volume remained unchanged in both teriparatide and placebo groups.

    In plain wordsIn kidney transplant recipients, microscopic bone volume remained unchanged in both teriparatide and placebo groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeHistomorphometric bone volume
    Study

    n = 12

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Lumbar spine and radial BMD, histomorphometric bone volume and bone matrix mineralization status remained unchanged in both groups.
    2 context sentences
    Summary · context
    Paired bone biopsies for histomorphometric analysis were obtained in six, and for measurement of bone matrix mineralization in five patients of each group.
    Summary · context
    In a 6-month double-blind, randomized trial, 26 kidney transplant recipients were treated with daily subcutaneous injections of 20 microg teriparatide (PTH 1-34) or placebo.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In kidney transplant recipients, bone matrix mineralization remained unchanged in both teriparatide and placebo groups.

    In plain wordsIn kidney transplant recipients, bone mineralization remained unchanged in both teriparatide and placebo groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone matrix mineralization
    Study

    n = 10

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Lumbar spine and radial BMD, histomorphometric bone volume and bone matrix mineralization status remained unchanged in both groups.
    2 context sentences
    Summary · context
    Paired bone biopsies for histomorphometric analysis were obtained in six, and for measurement of bone matrix mineralization in five patients of each group.
    Summary · context
    In a 6-month double-blind, randomized trial, 26 kidney transplant recipients were treated with daily subcutaneous injections of 20 microg teriparatide (PTH 1-34) or placebo.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.